# Sasikiran Nunna

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/sasikiran-nunna/

## Facts

| Field | Value |
| --- | --- |
| Citations | 136 |
| Field | Lipoproteins and Cardiovascular Health |
| h-index | 6 |
| i10-index | 5 |
| Last Known Institution | Otsuka (United States) |
| OpenAlex ID | https://openalex.org/A5057887317 |
| ORCID iD | 0000-0002-8006-7306 |
| Works | 54 |

## Researcher papers

- [Obesity Among High School Students in the United States: Risk Factors and Their Population Attributable Fraction](https://scholariq.org/papers/obesity-among-high-school-students-in-the-united-states-risk-factors-and-their/)
- [Geographic variations in lipid-lowering therapy utilization, LDL-C levels, and proportion retrospectively meeting the ACC/AHA very high-risk criteria in a real-world population of patients with major atherosclerotic cardiovascular disease events in the United States](https://scholariq.org/papers/geographic-variations-in-lipid-lowering-therapy-utilization-ldl-c-levels-and/)
- [Impact of Lurasidone and Other Antipsychotics on Body Weight: Real-World, Retrospective, Comparative Study of 15,323 Adults with Schizophrenia](https://scholariq.org/papers/impact-of-lurasidone-and-other-antipsychotics-on-body-weight-real-world/)
- [Tolvaptan and Kidney Function Decline in Older Individuals With Autosomal Dominant Polycystic Kidney Disease: A Pooled Analysis of Randomized Clinical Trials and Observational Studies](https://scholariq.org/papers/tolvaptan-and-kidney-function-decline-in-older-individuals-with-autosomal/)
- [Low‐density lipoprotein cholesterol lowering in real‐world patients treated with evolocumab](https://scholariq.org/papers/low-density-lipoprotein-cholesterol-lowering-in-real-world-patients-treated-with/)
- [Patient characteristics and acute cardiovascular event rates among patients with very high‐risk and non‐very high‐risk atherosclerotic cardiovascular disease](https://scholariq.org/papers/patient-characteristics-and-acute-cardiovascular-event-rates-among-patients-with/)
- [US Cost Burden of Relapsed Refractory Multiple Myeloma during Third and Later Lines of Treatment](https://scholariq.org/papers/us-cost-burden-of-relapsed-refractory-multiple-myeloma-during-third-and-later/)
- [<p>Demographic And Clinical Characteristics Of Patients Prescribed Proprotein Convertase Subtilisin/kexin Type 9 Inhibitor Therapy And Patients Whose Current Lipid-Lowering Therapy Was Modified</p>](https://scholariq.org/papers/and-lt-p-and-gt-demographic-and-clinical-characteristics-of-patients-prescribed/)
- [Lipid lowering therapy patterns and the risk of cardiovascular events in the 1-year after acute myocardial infarction in United Arab Emirates](https://scholariq.org/papers/lipid-lowering-therapy-patterns-and-the-risk-of-cardiovascular-events-in-the-1/)
- [Confirming the timing of phase-based costing in oncology studies: a case example in advanced melanoma](https://scholariq.org/papers/confirming-the-timing-of-phase-based-costing-in-oncology-studies-a-case-example/)
- [Treatment patterns, clinical outcomes, and economic burden among patients with immunoglobulin A nephropathy (IgAN) in China](https://scholariq.org/papers/treatment-patterns-clinical-outcomes-and-economic-burden-among-patients-with/)

## Researcher topics

- [Lipoproteins and Cardiovascular Health](https://scholariq.org/topics/lipoproteins-and-cardiovascular-health/)
- [Renal Diseases and Glomerulopathies](https://scholariq.org/topics/renal-diseases-and-glomerulopathies/)
- [Genetic and Kidney Cyst Diseases](https://scholariq.org/topics/genetic-and-kidney-cyst-diseases/)
- [Chronic Kidney Disease and Diabetes](https://scholariq.org/topics/chronic-kidney-disease-and-diabetes/)
- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)

## Researcher university

- [Otsuka (United States)](https://scholariq.org/institutions/otsuka-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.